<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2070-4909.2017.10.4.044-052</article-id><article-id custom-type="elpub" pub-id-type="custom">farmaec-218</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Foreign Experience</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Зарубежный опыт</subject></subj-group></article-categories><title-group><article-title>THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT</article-title><trans-title-group xml:lang="ru"><trans-title>МЕЖДУНАРОДНЫЙ ОПЫТ ЛЕКАРСТВЕННОГО ОБЕСПЕЧЕНИЯ НАСЕЛЕНИЯ В АМБУЛАТОРНОМ СЕКТОРЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукьянцева</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukyantseva</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лукъянцева Дарья Валерьевна – кандидат медицинских наук, старший научный сотрудник Центра финансов здравоохранения.</p><p>Настасьинский переулок, д. 3, стр. 2, Москва, 127006, тел.: +7(495)6998965</p></bio><bio xml:lang="en"><p>Lukyantseva Daria Valeryevna – PhD, Senior Researcher at the Center for Technology Assessment in Healthcare, the Institute of Applied Economic Research of RANEPA, Head of the Healthcare Finance Center.</p><p>Nastasiinsky lane d. 3 p. 2, Moscow, 127006, tel.: +7(495)6998965</p></bio><email xlink:type="simple">lukdaria@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мельникова</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mel’nikova</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мельникова Любовь Сергеевна – доктор медицинских наук, ведущий научный сотрудник Центра финансов здравоохранения.</p><p>Настасьинский переулок, д. 3, стр. 2, Москва, 127006, тел.: +7(495)6998965</p></bio><bio xml:lang="en"><p>Mel’nikova Lyubov’ Sergeevna – MD, Leading research fellow.</p><p>Nastasiinsky lane d. 3 p. 2, Moscow, 127006, tel.: +7(495)6998965</p></bio><email xlink:type="simple">lavrinenko-irina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Татаринов</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Tatarinov</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татаринов Антон Петрович – научный сотрудник Центра финансов здравоохранения.</p><p>Настасьинский переулок, д. 3, стр. 2, Москва, 127006, тел.: +7(495)6998965</p></bio><bio xml:lang="en"><p>Tatarinov Anton Petrovich – Researcher at the Center for Technology Assessment in Healthcare, the Institute of Applied Economic Research of RANEPA, Head of the Health Care Finance Center. </p><p>Nastasiinsky lane d. 3 p. 2, Moscow, 127006, tel.: +7(495)6998965</p></bio><email xlink:type="simple">tatarinov@hta-rus.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Научно-исследовательский финансовый институт» Министерства финансов Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>15</day><month>02</month><year>2018</year></pub-date><volume>10</volume><issue>4</issue><fpage>44</fpage><lpage>52</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Lukyantseva D.V., Mel’nikova L.S., Tatarinov A.P., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Лукьянцева Д.В., Мельникова Л.С., Татаринов А.П.</copyright-holder><copyright-holder xml:lang="en">Lukyantseva D.V., Mel’nikova L.S., Tatarinov A.P.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/218">https://www.pharmacoeconomics.ru/jour/article/view/218</self-uri><abstract><p>The paper examines the international experience of drug supply and the risks faced by countries using various systems of drug provision to the population in the outpatient settings. The option of introducing a system of drug supply or drug insurance with co-payment by outpatients is discussed.</p></abstract><trans-abstract xml:lang="ru"><p>В статье рассматривается международный опыт лекарственного обращения и те риски, с которыми столкнулись страны, применяющие различные системы лекарственного обеспечения населения при амбулаторном лечении. Обсуждается возможность введения лекарственного обеспечения или лекарственного страхования с возможностью сооплаты пациентами лекарственных препаратов в амбулаторном сегменте.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рынок лекарственных средств</kwd><kwd>система лекарственного обеспечения</kwd><kwd>медицинское страхование</kwd><kwd>финансирование и организация оказания медицинской помощи</kwd><kwd>международный опыт</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pharmaceutical market</kwd><kwd>drug supply</kwd><kwd>medical insurance</kwd><kwd>medical care</kwd><kwd>international practice</kwd><kwd>financial support of medical care</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pharmaceutical Financing Strategies. (MDS-3: Managing Access to Medicines and Health Technologies, Chapter 11), (2012; 18 pages). URL: http://apps.who.int/medicinedocs/documents/s19587en/s19587en.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Pharmaceutical Financing Strategies. (MDS-3: Managing Access to Medicines and Health Technologies, Chapter 11), (2012; 18 pages). URL: http://apps.who.int/medicinedocs/documents/s19587en/s19587en.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Доклад о состоянии здравоохранения в мире: Финансирование систем здравоохранения: Путь к всеобщему охвату населения медико-санитарной помощью; Всемирная организация здравоохранения, 2010 г. URL: http://www.who.int/whr/2010/whr10_ru.pdf?ua=1. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">World health report: Financing of health systems: A path to universal coverage of health care; World Health Organization 2010 (in Russian). URL: http://www.who.int/whr/2010/whr10_ru.pdf?ua=1. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 41. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 41. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Geneesmiddelenbulletin. The role of drug bulletins. Retrieved from http://geneesmiddelenbulletin.com/english/the-role-of-drugbulletins/.Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Geneesmiddelenbulletin. The role of drug bulletins. Retrieved from http://geneesmiddelenbulletin.com/english/the-role-of-drugbulletins/. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Specialisten schrijven specialistisch voor [Specialists prescribe specialist pharmaceuticals]. Pharmaceutisch Weekblad. 2003; 138 (17): 1. URL: http://www.sfk.nl/nieuws-publicaties/PW/2014/opnieuwminder-apotheken. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Specialisten schrijven specialistisch voor [Specialists prescribe specialist pharmaceuticals]. Pharmaceutisch Weekblad. 2003; 138 (17): 1. URL: http://www.sfk.nl/nieuws-publicaties/PW/2014/opnieuwminder-apotheken. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 275. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 275. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 149-150. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 149-150. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/data-en-feiten-2015/view. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/data-en-feiten-2015/view. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Prins M. A., Hek K., Verberne L., Nielen M., Opperhuizen G., Verheij R. Zorg door de huisarts: jaarcijfers 2014 en trendcijfers 2010- 2014 [Care provided by the GP, annual figures 2014 and trend figures 2010-2014]. URL: https://www.nivel.nl/sites/default/files/bestanden/dietist_jaarcijfers_2014.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Prins M. A., Hek K., Verberne L., Nielen M., Opperhuizen G., Verheij R. Zorg door de huisarts: jaarcijfers 2014 en trendcijfers 2010-2014 [Care provided by the GP, annual figures 2014 and trend figures 2010-2014]. URL: https://www.nivel.nl/sites/default/files/bestanden/dietist_jaarcijfers_2014.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Statistics Netherlands (2015). StatLine [online database]. The Hague/Heerlen: Statistics Netherlands. http://statline.cbs.nl. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Statistics Netherlands (2015). StatLine [online database]. The Hague/Heerlen: Statistics Netherlands. http://statline.cbs.nl. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Batenburg R., Kroneman M., Sagan A. The impact of the crisis on the health system and health in the Netherlands. Economic crisis, health systems and health in Europe. World Health Organization, Regional Office for Europe, European Observatory on Health Systems and Policies. 2015; URL: http://www.euro.who.int/__data/assets/pdf_file/0010/279820/Web-economic-crisis-health-systems-and-healthweb.pdf?ua=1. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Batenburg R., Kroneman M., Sagan A. The impact of the crisis on the health system and health in the Netherlands. Economic crisis, health systems and health in Europe. World Health Organization, Regional Office for Europe, European Observatory on Health Systems and Policies. 2015; URL: http://www.euro.who.int/__data/assets/pdf_file/0010/279820/Web-economic-crisis-health-systems-and-healthweb.pdf?ua=1. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 151. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 151. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">NPCF (2014). Voorlichting aan patiënt bij medicijnuitgifte nog niet in orde [Quality of information to patients at medicine delivery not yet satisfactory]. URL: https://www.patientenfederatie.nl/nieuws/voorlichting-aan-patient-bij-medicijnuitgifte-nog-niet-in-orde. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">NPCF (2014). Voorlichting aan patiënt bij medicijnuitgifte nog niet in orde [Quality of information to patients at medicine delivery not yet satisfactory]. URL: https://www.patientenfederatie.nl/nieuws/voorlichting-aan-patient-bij-medicijnuitgifte-nog-niet-in-orde. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/data-en-feiten-2015/view. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/data-en-feiten-2015/view. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">GlobalData, Singapore’s pharmaceutical market value to reach $1.15 billion by 202. URL: https://www.globaldata.com/singaporespharmaceutical-market-value-reach-1-15-billion-2021. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">GlobalData, Singapore’s pharmaceutical market value to reach $1.15 billion by 202. URL: https://www.globaldata.com/singaporespharmaceutical-market-value-reach-1-15-billion-2021. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pharmaceutical Inspection Co-operation Scheme. URL: https://www.picscheme.org/en/members?paysselect=SG. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Pharmaceutical Inspection Co-operation Scheme. URL: https://www.picscheme.org/en/members?paysselect=SG. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">GKV-Spitzenverband (2009). GKV-Arzneimittel-Schnellinformation (GAmSi). Essen, GKV-Spitzenverband. URL: http://www.gkv-gamsi.de. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">GKV-Spitzenverband (2009). GKV-Arzneimittel-Schnellinformation (GAmSi). Essen, GKV-Spitzenverband. URL: http://www.gkv-gamsi.de. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Verband der forschenden Pharma-Unternehmen (2012). General political situation. URL: https://www.vfa.de. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Verband der forschenden Pharma-Unternehmen (2012). General political situation. URL: https://www.vfa.de. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Statistisches Bundesamt (2014). Statistisches jahrbuch Deutschland und Internationales. URL: https://www.destatis.de/DE/Publikationen/StatistischesJahrbuch/StatistischesJahrbuch2014.pdf?__blob=publicationFile. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Statistisches Bundesamt (2014). Statistisches jahrbuch Deutschland und Internationales. URL: https://www.destatis.de/DE/Publikationen/StatistischesJahrbuch/StatistischesJahrbuch2014.pdf?__blob=publicationFile. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Schaufler J., Telschow C. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U., Paffrath D., eds. ArzneiverordnungsReport. 2013; 967-981. URL: https://link.springer.com/chapter/10.1007/978-3-642-37124-0_47. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Schaufler J., Telschow C. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U., Paffrath D., eds. Arzneiverordnungs-Report. 2013; 967-981. URL: https://link.springer.com/chapter/10.1007/978-3-642-37124-0_47. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Schaufler J., Telschow C. Überblick über die Arzneiverordnungen nach Arztgruppen. In: Schwabe U., Paffrath D., eds. ArzneiverordnungsReport 2013; 955-966. URL: https://link.springer.com/content/pdf/bfm%3A978-3-642-37124-0%2F1.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Schaufler J., Telschow C. Überblick über die Arzneiverordnungen nach Arztgruppen. In: Schwabe U., Paffrath D., eds. ArzneiverordnungsReport 2013; 955-966. URL: https://link.springer.com/content/pdf/bfm%3A978-3-642-37124-0%2F1.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bundesverband der Arzneimittel-Hersteller. Der Arzneimittelmarkt in Deutschland in Zahlen. Verordnungsmarkt und Selbstmedikation 2009. Bonn, Bundesverband der ArzneimittelHersteller. URL: https://www.bah-bonn.de/bah/?type=565&amp;file=redakteur_filesystem%2Fpublic%2Fmarkt_zahlen_broschuere_2010.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Bundesverband der Arzneimittel-Hersteller. Der Arzneimittelmarkt in Deutschland in Zahlen. Verordnungsmarkt und Selbstmedikation 2009. Bonn, Bundesverband der Arzneimittel-Hersteller. URL: https://www.bah-bonn.de/bah/?type=565&amp;file=redakteur_filesystem%2Fpublic%2Fmarkt_zahlen_broschuere_2010.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">OECD (2013). Health data 2011, 2012, 2013. Paris, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">OECD (2013). Health data 2011, 2012, 2013. Paris, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Data obrashcheniya: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Menon D., Stafinski T. Health technology assessment in Canada: 20 years strong? Value in Health. 2009; 12 (2): 14-19.</mixed-citation><mixed-citation xml:lang="en">Menon D., Stafinski T. Health technology assessment in Canada: 20 years strong? Value in Health. 2009; 12 (2): 14-19.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Flood C.M . The evidentiary burden for overturning government’s choice of regulatory instrument: the case of direct-to-consumer advertising of prescription drugs. University of Toronto Law Journal. 2010; 60 (2): 397-424.</mixed-citation><mixed-citation xml:lang="en">Flood C. M. The evidentiary burden for overturning government’s choice of regulatory instrument: the case of direct-to-consumer advertising of prescription drugs. University of Toronto Law Journal. 2010; 60 (2): 397-424.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mintzes B. с соавт. Influence of direct to consumer advertising and patients’ requests on prescribing decisions: two site cross sectional survey. BMJ. 2002; 324: 278-279.</mixed-citation><mixed-citation xml:lang="en">Mintzes B. s soavt. Influence of direct to consumer advertising and patients’ requests on prescribing decisions: two site cross sectional survey. BMJ. 2002; 324: 278-279.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Paris V., Docteur E. Pharmaceutical pricing and reimbursement policies in Canada. Paris, (Health Working Paper). Organisation for Economic Co-operation and Development. URL: http://www.oecdilibrary.org/social-issues-migration-health/pharmaceutical-pricingand-reimbursement-policies-in-canada_346071162287?crawler=true. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Paris V., Docteur E. Pharmaceutical pricing and reimbursement policies in Canada. Paris, (Health Working Paper). Organisation for Economic Co-operation and Development. URL: http://www.oecdilibrary.org/social-issues-migration-health/pharmaceutical-pricingand-reimbursement-policies-in-canada_346071162287?crawler=true. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Системы здравоохранения: время перемен. Реферат обзора: Канада, 2012 г.; Европейская обсерватория по системам и политике здравоохранения. URL: http://www.euro.who.int/__data/assets/pdf_file/0010/184672/Summary-HiT-Canada-2013-Rus.pdf?ua=1. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Health systems: the time of change. Review summary: Canada, 2012; European Observatory on Health Systems and Policies (in Russian). URL: http://www.euro.who.int/__data/assets/pdf_file/0010/184672/Summary-HiT-Canada-2013-Rus.pdf?ua=1. Accessed: 26.01.2018.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://publications.gc.ca/collections/Collection/CP32-85-2002E.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://publications.gc.ca/collections/Collection/CP32-85-2002E.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">McMahon M., Morgan S., Mitton C. The Common Drug Review: a NICE start for Canada? Health Policy. 2006; 77 (3): 339-351.</mixed-citation><mixed-citation xml:lang="en">McMahon M., Morgan S., Mitton C. The Common Drug Review: a NICE start for Canada? Health Policy. 2006; 77 (3): 339-351.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Menon D., Stafinski T., Stuart G. Access to drugs for cancer: does where you live matter? Canadian Journal of Public Health. 2005; 96 (6): 454-458.</mixed-citation><mixed-citation xml:lang="en">Menon D., Stafinski T., Stuart G. Access to drugs for cancer: does where you live matter? Canadian Journal of Public Health. 2005; 96 (6): 454-458.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Grootendorst P., Hollis A. Managing pharmaceutical expenditures: overview and options for Canada. Ottawa, Canadian Health Services Research Foundation. URL: http://www.cfhi-fcass.ca/Libraries/Hospital_Funding_docs/CHSRF-GrootendorstPharmaExpenditures.sflb.ashx. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Grootendorst P., Hollis A. Managing pharmaceutical expenditures: overview and options for Canada. Ottawa, Canadian Health Services Research Foundation. URL: http://www.cfhi-fcass.ca/Libraries/Hospital_Funding_docs/CHSRF-GrootendorstPharmaExpenditures.sflb.ashx. Accessed: 25.10.2017</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">McLeod L. et al. Financial burden of household out-of-picket expenditures for prescription drugs: cross-sectional analysis based on national survey data. Open Medicine. 2011; 5 (1): 1-9.</mixed-citation><mixed-citation xml:lang="en">McLeod L. et al. Financial burden of household out-of-picket expenditures for prescription drugs: cross-sectional analysis based on national survey data. Open Medicine. 2011; 5 (1): 1-9.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Pomey M. P. et al. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec’s universal drug insurance program, with comparisons to the medicare Prescription Drug program. Milbank Quarterly. 2007; 85 (3): 469-498.</mixed-citation><mixed-citation xml:lang="en">Pomey M. P. et al. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec’s universal drug insurance program, with comparisons to the medicare Prescription Drug program. Milbank Quarterly. 2007; 85 (3): 469-498.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://www.cbc.ca/healthcare/final_report.pdf. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://www.cbc.ca/healthcare/final_report.pdf. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell B., Marchildon G. P. с соавт. Federal Pharmacare: prescription for an ailing federation? Medicare: facts, myths, problems and promise. Toronto, Lorimer. 2007; 268-284.</mixed-citation><mixed-citation xml:lang="en">Campbell B., Marchildon G. P. s soavt. Federal Pharmacare: prescription for an ailing federation? Medicare: facts, myths, problems and promise. Toronto, Lorimer. 2007; 268-284.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">OECD (2014). Health at a glance: Europe 2014. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">OECD (2014). Health at a glance: Europe 2014. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">OECD (2012). Pharmaceutical spending. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">OECD (2012). Pharmaceutical spending. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">O’Neill C., McGregor P., Merkur S. United Kingdom (Northern Ireland) health system review. Health Systems in Transition. 2012; 14 (10): 1-90.</mixed-citation><mixed-citation xml:lang="en">O’Neill C., McGregor P., Merkur S. United Kingdom (Northern Ireland) health system review. Health Systems in Transition. 2012; 14 (10): 1-90.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Health &amp; Social Care Information Centre (2014). Prescription dispensed in the community, Statistics for England, 2003-2013. URL: https://digital.nhs.uk/catalogue/PUB14414. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Health &amp; Social Care Information Centre (2014). Prescription dispensed in the community, Statistics for England, 2003-2013. URL: https://digital.nhs.uk/catalogue/PUB14414. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Department of Health (2013). Government agrees breakthrough drug pricing deal with pharmaceutical firms. London, Department of Health. URL: https://www.gov.uk/government/news/governmentagrees-breakthrough-drug-pricing-deal-with-pharmaceutical-firms. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Department of Health (2013). Government agrees breakthrough drug pricing deal with pharmaceutical firms. London, Department of Health. URL: https://www.gov.uk/government/news/governmentagrees-breakthrough-drug-pricing-deal-with-pharmaceutical-firms. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Y. с соавт. Medicine expenditures. In: The world medicines situation. Geneva, World Health Organization. 2010. URL: http://dosei.who.int/. Дата обращения: 25.10.2017.</mixed-citation><mixed-citation xml:lang="en">Lu Y. s soavt. Medicine expenditures. In: The world medicines situation. Geneva, World Health Organization. 2010. URL: http://dosei.who.int/. Accessed: 25.10.2017.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
